Anavex Life Sciences Corp (AVXL)

[falconer66a]

The Anavex 2-73 Patent

Here’s its abstract (summary);

ABSTRACT
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3- furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2- diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).

First, my comments are merely personal thoughts. I have no particular expertise on patent law or applications.

I do, however, believe the text of the application is carefully exclusive, keeping out other, similar molecules that might be mere tweakings of the Anavex molecule. Those new molecules would be chemically different from the prime one, central to CNS treatment; but nonetheless equally effective. If these were allowed, if the Anavex molecule patent were not protctive, other companies could create re-configured tweakings as competing new drugs.

But, the text, “... includes the polymorphic forms ...” appears to preclude this. Of course, the legal and chemical experts Anavex has certainly retained to create air-tight legal text have done their jobs, probably more extensively than my single observation here.

I’ve had no intellectual property concerns about Anavex and its new molecules. Anavex executives knew from the start that intellectual property issues would have to be exhaustively explored and resolved. Not an issue whatsoever. Patent lawyers have done their jobs, certainly.